Diet Pill Online > Tag cloud > rimonabant

Acomplia has been developed from the knowledge that cannabis smokers often experience extreme hunger pangs, which cannabis smokers refer to as 'the munchies'.

Acomplia works by blocking endogenous cannabinoid binding to neuronal CB1 receptors. Activation of these receptors by endoegenous cannabinoids, such as anadamide, increases appetite.

Filed for approval with the FDA in April 2005, it has encountered significant delays over the past two years. In February 2007, the company learnt that the FDA had extended their decision on whether or not to approve Acomplia by a further 3 months. Despite the repeated setbacks, analysts remain optimistic that it will eventually be approved in the US as an aid to weight loss.

A second name trademarked by Sanofi-Aventis, in addition to Acomplia, for rimonabant is Zimulti. You might see the drug adverted by either name, such as SR141716, Bethin, Monaslim, Remonabent, Riobant, Slimona and Rimoslim.

At this time it seems like Sanofi is likely to practice the name Zimulti in America and Acomplia in Europe. As of June, 2006, when rimonbant was approved for sale in Europe, "Acomplia" was indeed the name chosen for European sale and Zimulti for US sale.